BiotechTube

Placebo + Secukinumab 150mg + Secukinumab 300mg

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque-type Psoriasis

Conditions

Plaque-type Psoriasis

Trial Timeline

Oct 17, 2012 → Oct 27, 2016

NCT ID
NCT01636687

About Placebo + Secukinumab 150mg + Secukinumab 300mg

Placebo + Secukinumab 150mg + Secukinumab 300mg is a phase 3 stage product being developed by Novartis for Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01636687. Target conditions include Plaque-type Psoriasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01636687Phase 3Completed

Competing Products

18 competing products in Plaque-type Psoriasis

See all competitors
ProductCompanyStageHype Score
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
77
AIN457 150 mg + AIN457 300 mg + PlaceboNovartisPhase 3
77
AIN457 + AIN457A + AIN457A + PlaceboNovartisPhase 2
52
secukinumab + placeboNovartisPhase 2
52
secukinumab 150 mgNovartisPhase 3
77
Experimental : Secukinumab low dose + Experimental: Secukinumab high dose + Placebo Comparator: Secukinumab Placebo + Active Comparator: EtanerceptNovartisPhase 3
77
SecukinumabNovartisPhase 3
77
AIN457 + PlaceboNovartisPhase 2
52
Secukinumab (AIN457) + PlaceboNovartisPhase 3
77
secukinumab 150 mg + placebo to secukinumab 150 mgNovartisPhase 3
77
secukinumab low dose + secukinumab high doseNovartisPhase 3
77
AIN457 150mg + AIN457 300mgNovartisPhase 3
77
secukinumab 150mg + secukinumab 10mg/kg i.v. regimenNovartisPhase 3
77
CJM112 + SecukinumabNovartisPhase 1
33
secukinumab 150 mg + secukinumab 300 mg + placeboNovartisPhase 3
77
AIN457 + PlaceboNovartisPhase 2
52
AN2728 Ointment + AN2728 VehiclePfizerPhase 1
32
Olux-E Foam + Clobex lotionGSK plcApproved
84

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85